Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine in Combination With DA-EPOCH-R in Untreated Aggressive B-cell Lymphoma
NCT05270057Phase 1Active, not recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Jan 2023
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of loncastuximab tesirine in B cell lymphoma and Burkitt lymphoma (BL) (5 arms), sponsored by Medical College of Wisconsin. Primary endpoints: Maximum Tolerated Dose up to 21 days and Dose-Limiting Toxicities up to 21 days. Started Jan 2023; status: active, not recruiting.
02
Drugs
loncastuximab tesirine
03
Conditions
B cell lymphomaBurkitt lymphoma (BL)
Beyond the preview
Go deeper on NCT05270057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05270057.